Efficacy of chemotherapy in extremely elderly patients with diffuse large B-cell lymphoma.

Abstract

The safety and effective dose of chemotherapy in treating non-Hodgkin lymphoma in elderly patients is yet to be established. In this study, we assessed the prognosis of diffuse large B-cell lymphoma (DLBCL) in elderly patients (≥75 years) treated with an optimal dose of R-CHOP. No significant differences were observed in progression-free survival between elderly patients and patients aged <74 years with DLBCL. Furthermore, no differences were observed between full-dose R-CHOP and 80% dose R-CHOP groups. Median relative dose intensity was 0.80 in elderly patients with DLBCL. Thus, our data suggested that 80% dose R-CHOP is tolerable and effective in these patients.

• Authors: Anna Takahashi, Yuko Mishima, Masahiro Yokoyama, Norihito Inoue, Yoshiharu Kusano, Tadahiro Gunji, Hideaki Nitta, Kyoko Ueda, Noriko Nishimura, Naoko Tsuyama, Kengo Takeuchi, Yasuhito Terui, Kiyohiko Hatake
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 58 Issue 5 Pg. 427-432 ( 2017) ISSN: 0485-1439 [Print] Japan
• PMID: 28592754 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• R-CHOP protocol
• Rituximab
• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Adult
• Aged
• Aged, 80 and over
• Antibodies, Monoclonal, Murine-Derived (adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Cyclophosphamide (adverse effects, therapeutic use)
• Doxorubicin (adverse effects, therapeutic use)
• Female
• Humans
• Lymphoma, Large B-Cell, Diffuse (drug therapy)
• Male
• Middle Aged
• Multivariate Analysis
• Prednisone (adverse effects, therapeutic use)
• Rituximab
• Treatment Outcome
• Vincristine (adverse effects, therapeutic use)
• Young Adult